About 2 results found for searched term "DCC-2618" (0.164 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M9903 | Ripretinib | c-Kit |
| DCC-2618 | ||
| Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFR-alpha inhibitor. | ||
| M20635 | DCC-2618 | c-Kit |
| DCC-2618 is an orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of KIT and PDGFR with potential antineoplastic activity. It also inhibits several other kinases, including VEGFR2, TIE2, PDGFR-beta and CSF1R, thereby further inhibiting tumor cell growth. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
